Friday, 16 October 2026European Markets

SEADRILL Stock Bullish Momentum With A 29% Jump In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of SEADRILL (Oslo Børs All-share Index_GI: SDRL.OL) jumped by a staggering 29.37% in 21 sessions from 331.1 kr to 428.35 kr at 04:40 EST on Friday, after two consecutive sessions in a row of gains. Oslo Børs All-share Index_GI is sliding 0.2% to 1,413.04 kr, after three consecutive sessions in a row of losses.

SEADRILL's last close was 453.00 kr, 2.48% higher than its 52-week high of 442.05 kr.

About SEADRILL

Seadrill Limited provides offshore contract drilling services to the oil and gas industry worldwide. It operates in three segments: Harsh Environment, Floaters, and Jack-ups Rigs. The company owns and operates drillships, semi-submersible rigs, and jack-up rigs for operations in shallow and ultra-deep-water in benign and harsh environments. It offers operation support and management services to third parties, as well as related and non-related companies. As of April 8, 2022, the company owned a fleet of 21 offshore drilling units consisting of two harsh-environment rigs, two benign-environment semi-submersible rigs, six drill-ships, and 11 jack-up rigs. It serves oil super-majors, state-owned national oil companies, and independent oil and gas companies. Seadrill Limited was incorporated in 2005 and is headquartered in London, the United Kingdom.

Earnings Per Share

As for profitability, SEADRILL has a trailing twelve months EPS of -386.25 kr.

Revenue Growth

Year-on-year quarterly revenue growth grew by 21.4%, now sitting on 1.09B for the twelve trailing months.

Moving Average

SEADRILL's worth is way higher than its 50-day moving average of 334.71 kr and way above its 200-day moving average of 308.98 kr.

More news about SEADRILL (SDRL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com